ERas Enhances Resistance to CPT-11 in Gastric Cancer
By: Kubota E, Kataoka H, Tanaka M, Okamoto Y, Ebi M, Hirata Y, Murakami K, Mizoshita T, Shimura T, Mori Y, Tanida S, Kamiya T, Aoyama M, Asai K, Joh T.

Department of Gastroenterology and Metabolism, Nagoya City University, Graduate School of Medical Sciences. 1 Kawasumi, Mizuho, Nagoya, 467-8601, Japan. hkataoka@med.nagoya-cu.ac.jp.
Anticancer Res. 2011 Oct; 31(10):3353-60.

Abstract

Background/Aim

We have reported that embryonic stem cell-expressed Ras (ERas) is expressed in human gastric cancer and is associated with its tumorigenicity. Here, we asked whether ERas plays a role in resistance to chemotherapy in gastric cancer.

Materials and Methods

To assess the cytotoxicity of chemotherapeutic agents, ERas-overexpressing human gastric cancer GCIY cells were exposed to anticancer agents, including CPT-11 and inhibitor of mammalian target of rapamycin (mTOR). We also investigated the mechanisms by which ERas induces chemoresistance.

Results

ERas-overexpressing clones were significantly more resistant to CPT-11 than were the control (p<0.001). Administration of rapamycin was significantly cytotoxic to the ERas-overexpressing clones compared with the control (p<0.01). Electrophoresis mobility shift assay revealed that ERas enhanced nuclear factor (NF)-κB activity. PCR array demonstrated that ERas up-regulated several multidrug efflux transporter genes, including ABCG2.

Conclusion

ERas induces chemoresistance to CPT-11 via activation of phosphatidylinositol-3 kinase-protein kinase β mTOR pathway and NF-κB, and consequently results in up-regulation of ABCG2.

PMID: 21965746 Source: National Library of Medicine.







Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements